Just a quick post to say we'll be interviewing Abcam on Friday, and if anyone has any questions for the company to post them here or send them via the Contact Form. If you don't know Abcam, it's one of AIM's greatest successes of recent years with an 854% share price appreciation since float in 2005. You can watch a video with the CEO here.

The company is extremely simple, it sells antibodies to research scientists through an online catalogue and has posted a return on capital of between 30% and 50% every year since float. According to various sources, the market is worth about $1bn and is growing up to 10% annually - Abcam is by now possibly the market leader with a forecast £85m in annual sales forecast for 2011.  Due to its tremendous track record, the company trades on a forecast multiple of 28 times 12 month earnings.


Unlock the rest of this Article in 15 seconds

or Unlock with your email